TNBC is known for its aggressive nature and limited treatment options; however, checkpoint blockade therapy has demonstrated significant benefits in patients with PD-L1-positive tumors by reinvigorating exhausted T cells and restoring anti-tumor immune responses. Here, CD274 is linked to neoplasm.